Trial Profile
Evaluation of the pharmacokinetics and tolerability of increased dosage of lopinavir/ritonavir(LPV/r) [Kaletra] in individuals experiencing viremia on standard dose LPV/r using LPV/r tablet formulation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Acronyms BOOST
- 07 Dec 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 Jan 2007 New trial record.